PHYTOCHEMICAL ANALYSIS, IN-VITRO AND IN-VIVO PHARMACOLOGICAL EVALUATION OF DRYOPTERIS JUXTAPOSITA CHRIST (FRONDS)

Le résumé fourni par la source

Natural product research is one of the keys towards the development of pharmaceuticals. Due to the lack of understanding of the causes of many human, animal, and plant diseases, these challenging chemical compounds have the potential to be active therapeutics. In this research, a frond of the plant was collected in Shangla District, Khyber Pakhtunkhwa during May. It was identified as Dryopteris Juxtaposita Christ, Fronds are used locally to treat stomach ulcers, bone problems, constipation and also in vegetables. Shade-dried plant material was pulverized and extracted into methanol. It was then subfractionated into aqueous, ethyl acetate-hexane and chloroform fractions. Preliminary phytochemical investigation was done to find the primary and secondary metabolites in the sample. The organic extract was tested for antidepressant and antibacterial activity. The crude extract had very little effect compared to regular imipramine in the forced swimming test to evaluate antidepressant efficacy. Additionally, the fractions of the crude extract showed a certain amount of antibacterial activity. When it came to Salmonella typhi, the ethyl acetate fraction had the most activity (60%) and Escherichia coli, the n-hexane fraction had the highest activity (46.43%). Other fractions, though, showed minimal antimicrobial activity. Phytochemical analysis of the crude extract of the Fronds of Dryopteris Juxtaposita Christ revealed the presence of a high concentration of amino acids, proteins, tannins, saponins and cardiac glycosides in all extracts/fractions. Whereas, no lipids but trace amounts of steroids were detected in these extracts/fractions. Based on the appreciable activities this plant should be further studied to isolate and identify additional bioactive compounds. To determine possible In-vivo effects of different isolated compounds having potent antioxidant, cytotoxic activities and anticancer activities against known cancer cell lines. This will lead to the development of safe pharmaceuticals.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.